Godavari Biorefineries Ltd

Godavari Biorefineries Launches US Subsidiary for Cancer Drug Discovery 🎯💊

- Godavari Biorefineries Ltd (GBL) establishes Sathgen Therapeutics LLC, a US-based subsidiary focused on drug discovery.

- Sathgen will specialize in triple-negative breast cancer (TNBC) and other aggressive cancers.

- Dr. Padmaja Ganapathy named CEO; Dr. Sendurai Mani appointed Chief Scientific Officer.

- Patents secured in US, Europe, China for novel cancer stem cell-targeting molecules.

- Scientific Advisory Board formed with experts like Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli.

- GBL shifts focus from generics to original drug discovery in high-need areas.

- US subsidiary to enhance research collaborations and clinical program development.

- GBL maintains bio-based chemical, ethanol, and sugar & power production in India with sustainability focus.